Pharmaceuticals, Biotechnology and Life Sciences
Week 96 data from the BRIGHTE study of first-in-class fostemsavir continue to show improvement in virologic suppression and immunologic response…
Yellow Wood Partners will buy the Dr. Scholl’s foot care business from Bayer for a purchase price of $585 million, the companies said amid Bayer’s voluntarily recall of a product in the USA.
Bayer is voluntarily recalling two lots of Kogenate FS antihemophilic factor (recombinant) 2000 IU vials in the United States to the patient level, the company said Monday in a statement.
-Application supported by positive results from two global Phase 3 studies in people with CF ages 12 and older with…
Dr.Reddy’s has launched OTC store-brand equivalent of Allegra-D 12 HR Allergy and Congestion Extended-Release Tablets, in the United States market, as approved by the U.S. Food and Drug Administration.
Sensient Technologies today announced the election of Carol Jackson to its Board of Directors, effective December 1, 2019.
Bayer, Bristol-Myers Squibb Company (NYSE: BMY) and Ono Pharmaceutical Co., Ltd. (“Ono”) announced today the three companies have entered into a clinical collaboration agreement to evaluate the combination of Bayer’s kinase inhibitor Stivarga® (regorafenib) and Bristol-Myers Squibb’s / Ono’s anti-PD-1 immune checkpoint inhibitor, Opdivo® (nivolumab) in patients with micro-satellite stable metastatic colorectal cancer (MSS mCRC), the most common form of mCRC.1
Key data now being collected to support endpoint assessment for future gene therapy clinical trial NEW YORK–(BUSINESS WIRE)–Neurogene Inc., a…
Nexien BioPharma was granted patent for “Use of Cannabinoids and Terpenes for Treatment of Organophosphate and Carbamate Toxicity” by the Israeli Patent Office.
BOSTON–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2019 financial results on Wednesday, July 31, 2019 after…